Gland Pharma's Dundigal facility receives EIR report from USFDA

Gland Pharma announced that following the Pre-Market Inspection covering US FDA's Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) at the Company's Dundigal Facility at Hyderabad from 22 August 2022 to 25 August 2022; the Company has received the Establishment Inspection Report (EIR) from the Office of Product Evaluation and Quality Center for Devices and Radiological Health, US FDA indicating closure of the inspection.

Powered by Capital Market - Live News